Compare iShares China Large-Cap ETF (FXI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Neurocrine Biosciences Inc — how do they compare? iShares China Large-Cap ETF trades at $35.22, while Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | NBIX | |
|---|---|---|
52-Week High | $41.75 | $185.50 |
52-Week Low | $31.59 | $123.10 |
Market Cap | — | $16.46B |
Sector | — | Health |
Enterprise Value | — | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $35.23, down 3.45% on the day amid broader Chinese stock pressure. Technical indicators show a bullish overall signal with moving averages supporting upside momentum, while oscillators remain neutral. The ETF benefits from China's export strength and AI-driven manufacturing rebound, though financial ratios are currently unavailable. Recent news highlights China's 23% July export growth and ongoing infrastructure investments to support economic stability.
FXI offers exposure to China's large-cap recovery with state-backed stimulus and AI export growth as key catalysts. However, geopolitical tensions and US-China tech restrictions pose significant risks. The ETF's heavy financial sector weighting provides stability but limits pure tech exposure, requiring careful monitoring of China's economic policies and global trade dynamics.
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
